Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04155619 · ClinicalTrials.gov registry record · NA

Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes

A NA study of Diabetes Mellitus, Type 2 and Time Restricted Feeding, sponsored by University of Alabama at Birmingham.

Active
Registry status
NA
Development phase
344
Enrollment target
1
Study location

NCT04155619: Active NA study of Diabetes Mellitus, Type 2 and Time Restricted Feeding, sponsored by University of Alabama at Birmingham.

NCT04155619 is a NA study of Diabetes Mellitus, Type 2 and Time Restricted Feeding that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 344 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04155619, a NA study of Diabetes Mellitus, Type 2 and Time Restricted Feeding, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
344 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test whether eating earlier in the day and/or timed light therapy can improve blood sugar in people with type 2 diabetes. This study will also test whether these treatments improve other aspects of health, including the circadian (biological) clock, sleep, weight, body composition, cardiovascular health, quality of life, and mood.

Primary Outcome

Time-weighted mean, fasting, peak, standard deviation, and excursion (maximum - minimum) values (mg/dl)

Interventions

  • BEHAVIORAL No change in meal timing
  • BEHAVIORAL No change in light exposure
  • BEHAVIORAL Early Time-Restricted Feeding
  • BEHAVIORAL Timed Light Therapy

Study Locations (1)

Alabama

  • University of Alabama at Birmingham; Birmingham Veterans Affairs Medical Center - Birmingham

Trial Details

FieldValue
Enrollment Target 344 participants
Start Date 2021-04-26
Est. Completion 2026-08
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the registry record for NCT04155619 still lists

NCT04155619 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which No change in meal timing is the first listed.

NCT04155619 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT04155619 about?

NCT04155619 is a clinical study titled "Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes". The purpose of this study is to test whether eating earlier in the day and/or timed light therapy can improve blood sugar in people with type 2 diabetes. This study will also test whether these treatments improve other aspects of health, including the circadian (biological) clock, sleep, weight, bod...

What is the current status of trial NCT04155619?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 344 participants. The study started on 2021-04-26. Estimated completion is 2026-08.

What conditions does trial NCT04155619 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications.

What interventions are being tested in trial NCT04155619?

The interventions under investigation include: No change in meal timing (BEHAVIORAL), No change in light exposure (BEHAVIORAL), Early Time-Restricted Feeding (BEHAVIORAL), Timed Light Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT04155619?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04155619 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04155619's enrollment target sits among peer trials

344 105th of 348 higher than 244 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06733363 · 344 participants · Phase 2

    A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

  • NCT07179380 · 344 participants · Phase 3

    Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • NCT07304024 · 344 participants · Phase 1

    A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

  • NCT03972657 · 345 participants · Phase 1

    A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04155619, the US trial registry maintained by the National Library of Medicine. NCT04155619 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.